Encompass Health Corporation $EHC Shares Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd lifted its position in Encompass Health Corporation (NYSE:EHC) by 37.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,110 shares of the company’s stock after acquiring an additional 1,930 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Encompass Health were worth $872,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in EHC. Invesco Ltd. grew its stake in Encompass Health by 5.1% during the 1st quarter. Invesco Ltd. now owns 5,818,783 shares of the company’s stock valued at $589,326,000 after acquiring an additional 282,532 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Encompass Health by 25.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company’s stock worth $210,756,000 after acquiring an additional 424,691 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Encompass Health by 5.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company’s stock valued at $189,549,000 after buying an additional 93,992 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Encompass Health by 13.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company’s stock valued at $184,571,000 after acquiring an additional 211,707 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Encompass Health by 0.5% during the second quarter. Geode Capital Management LLC now owns 1,773,547 shares of the company’s stock worth $217,526,000 after purchasing an additional 8,765 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Trading Up 1.5%

NYSE EHC opened at $114.44 on Friday. Encompass Health Corporation has a 52 week low of $87.85 and a 52 week high of $127.99. The firm has a 50 day moving average of $121.34 and a two-hundred day moving average of $119.54. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $11.51 billion, a PE ratio of 21.63, a price-to-earnings-growth ratio of 2.20 and a beta of 0.91.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. The business had revenue of $136.30 million during the quarter. Encompass Health had a net margin of 9.33% and a return on equity of 18.19%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. As a group, research analysts expect that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Friday, January 2nd will be issued a $0.19 dividend. The ex-dividend date is Friday, January 2nd. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio is presently 14.37%.

Insider Buying and Selling at Encompass Health

In related news, EVP Patrick William Tuer sold 1,020 shares of the business’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the sale, the executive vice president owned 18,846 shares in the company, valued at $2,329,177.14. The trade was a 5.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. KeyCorp lifted their target price on Encompass Health from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Wall Street Zen lowered shares of Encompass Health from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. UBS Group upped their target price on shares of Encompass Health from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Raymond James Financial raised shares of Encompass Health to a “strong-buy” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “buy (b+)” rating on shares of Encompass Health in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $142.86.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.